Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Pricing and Reimbursement in Generics - Introduction | 7 | 2 |
| GBI Research Report Guidance | 8 | 1 |
| Pricing and Reimbursement in Generics - The US | 9 | 21 |
| Health Insurance | 10 | 1 |
| Health Insurance Coverage | 10 | 1 |
| Health Insurance Providers | 10 | 1 |
| Public Health Insurance | 10 | 1 |
| Private Health Insurance | 11 | 1 |
| Major Agencies Involved | 12 | 1 |
| Structure of Regulatory System | 12 | 1 |
| Pricing of Generics in the US | 12 | 2 |
| 340B Drug Pricing Program | 14 | 1 |
| Reimbursement of Generics in the US | 15 | 1 |
| Health Insurance Companies | 16 | 1 |
| Pharmacy Benefit Managers | 16 | 1 |
| Reimbursement Programs in the US | 17 | 1 |
| Case Studies | 18 | 1 |
| Discount Programs in Other States | 19 | 1 |
| Case Study | 20 | 1 |
| Pricing and Reimbursement in Oncology | 20 | 1 |
| Key Trends | 20 | 1 |
| Increased Availability of Generic Drugs | 20 | 1 |
| Patient Protection and Affordable Care Act to Tackle Soaring Prescription Drug Prices | 21 | 2 |
| Significant Decrease in Average Price of Generic Drugs | 23 | 1 |
| Generic Drugs Rebates to be Aligned for Medicare and Medicaid | 23 | 1 |
| Lower FEHB Drug Costs | 24 | 1 |
| Medicare Part D Changes in Standard Benefit Parameters | 24 | 2 |
| Cost-sharing of Generic Drugs | 26 | 1 |
| Penalty for Anemia Drug Overuse | 27 | 1 |
| Generic Price War at Retail Sector | 27 | 1 |
| Major Challenges | 28 | 1 |
| Medicare Part B Drug Pricing Does Not Accurately Reflect Market Price | 28 | 1 |
| Renewal of Medicaid Drug Payment Policy | 28 | 1 |
| Proposed Cuts in Medicare Part B Reimbursement | 28 | 1 |
| New Trend in Free Trade Agreements Could Affect Healthcare Programs | 29 | 1 |
| Pricing and Reimbursement in Generics - The Top Five Countries of Europe | 30 | 18 |
| The UK | 30 | 1 |
| Pricing and Reimbursement Process | 31 | 1 |
| Key Trends | 31 | 1 |
| Generic Substitution Not Implemented | 31 | 1 |
| Major Challenges | 32 | 1 |
| France | 32 | 1 |
| Pricing and Reimbursement Process | 33 | 1 |
| Important Players | 33 | 1 |
| Financing Law of Social Security 2011 | 34 | 1 |
| Key Trends | 35 | 1 |
| Austerity Plan to Cut 2012 Healthcare Budget | 35 | 1 |
| Pharmaceutical Drug Spending Set for Decline | 35 | 1 |
| CEPS Adjustments to Drug Pricing Methods | 35 | 1 |
| Generics Substitution Missed Targets in 2010 - More Robust Measures Likely In Future | 35 | 1 |
| CEPS Sets Up New Reference Prices Generic Groups | 36 | 1 |
| Exclusion of Benign Hypertension from Reimbursement | 36 | 1 |
| Reimbursement Restrictions for Drugs of Limited Clinical Merit Rating | 36 | 1 |
| Reimbursement Cuts for Drugs with Moderate Clinical Benefit | 36 | 1 |
| Swift End to Reimbursement of Drugs That Offer Minimal Clinical Benefit | 36 | 1 |
| Major Challenges | 37 | 1 |
| Generic versus Brand Name Drugs | 37 | 1 |
| Germany | 37 | 1 |
| Pricing and Reimbursement Process | 38 | 1 |
| Generic Drugs Reimbursement Prices | 39 | 1 |
| Key Trends | 40 | 1 |
| Cost Containment Measures | 40 | 1 |
| Rebate Contracts between Health Insurance Funds and Manufacturers of Generics | 40 | 1 |
| Major Challenges | 40 | 1 |
| Italy | 41 | 1 |
| Pricing and Reimbursement Process | 42 | 1 |
| Key Trends | 42 | 1 |
| Italian P&R Scene Dominated By Price Cuts and Changes in Reference Price Level | 43 | 1 |
| Austerity Package to Affect All the Stakeholders in the Pharmaceutical Industry Chain | 43 | 1 |
| Margin Cuts Of Wholesaler and Pharmacists on Top of Price Limits | 43 | 1 |
| Major Challenges | 44 | 1 |
| Challenge for Generic Drug Producers | 44 | 1 |
| Spain | 44 | 1 |
| Pricing and Reimbursement Process | 45 | 1 |
| Key Trends | 45 | 1 |
| New Royal Decree to Improve Pharmaceutical Spending and Quality of NHS | 46 | 1 |
| Change in the Reference Pricing System | 46 | 1 |
| Average Price Cut of 25% on Generic Drugs | 46 | 1 |
| Further Pricing Pressure Due to Tendering System and Other Demand-Side Initiatives by Regional Authorities | 46 | 1 |
| Generic Drugs on the Rise | 47 | 1 |
| Major Challenges | 47 | 1 |
| Pricing and Reimbursement in Generics - Eastern Europe | 48 | 13 |
| Czech Republic | 48 | 1 |
| Pricing and Reimbursement Process | 48 | 1 |
| Key Trends | 49 | 1 |
| Plans for Pharmacy Discounts | 49 | 1 |
| 7% Reduction of Drug Prices for Drugs Not Reviewed by SUKL Valid for One Year | 49 | 1 |
| Changes in VAT on Medicines Expected From 2012 | 49 | 1 |
| Major Challenges | 50 | 1 |
| Poland | 50 | 1 |
| Pricing and Reimbursement Process | 51 | 1 |
| Key Trends | 51 | 1 |
| Removal of the Proposed 3% Tax in the Initial Draft of Reimbursement Act | 52 | 1 |
| Expenditure on Reimbursement of Medicines Fixed at 17% of the NHF | 52 | 1 |
| Fixed Price on Reimbursed Medicines | 52 | 1 |
| Margins of Wholesalers to Be Reduced Periodically | 52 | 1 |
| Major Challenges | 52 | 1 |
| Austria | 53 | 1 |
| Pricing and Reimbursement Process | 53 | 1 |
| Key Trends | 54 | 1 |
| Romania | 54 | 1 |
| Pricing and Reimbursement Process | 54 | 1 |
| Key Trends | 55 | 1 |
| New International Reference Pricing Will Give a Boost to Generics Producers | 55 | 1 |
| Change in Reference Price Calculation | 55 | 1 |
| New Reimbursement Method for C2 Drugs | 55 | 1 |
| Major Challenges | 56 | 1 |
| Claw-back System Threatens Pharmaceutical Market | 56 | 1 |
| Extension in Drug Reimbursement Period | 57 | 1 |
| Case Study | 57 | 1 |
| Hungary | 57 | 1 |
| Pricing and Reimbursement Process | 58 | 1 |
| Key Trends | 59 | 1 |
| Price Reductions due to Quarterly Price Competition Program between Generic Manufacturers | 59 | 1 |
| Price Fixing Of Composite Drugs to Deliver Savings | 59 | 1 |
| Increase in Levy on Revenue from Reimbursed Drugs Sale from 12% to 20% | 59 | 1 |
| Generics Set for Further 5% Reference Price Reductions | 60 | 1 |
| Limited Reimbursement for Uncooperative Patients | 60 | 1 |
| New Price Bidding System | 60 | 1 |
| Major Challenges | 60 | 1 |
| Pricing and Reimbursement in Generics - Scandinavia | 61 | 11 |
| Norway | 61 | 1 |
| Pricing and Reimbursement Process | 61 | 2 |
| Contribution System | 63 | 1 |
| Hospital Pricing and Reimbursement | 63 | 1 |
| Key Trends | 64 | 1 |
| Sweden | 64 | 1 |
| Pricing and Reimbursement Process | 64 | 2 |
| Major Challenges | 66 | 1 |
| Finland | 66 | 1 |
| Pricing and Reimbursement Process | 67 | 2 |
| Denmark | 69 | 1 |
| Pricing and Reimbursement Process | 69 | 2 |
| Key Trends | 71 | 1 |
| Pricing and Reimbursement in Generics - Asia-Pacific | 72 | 20 |
| Japan | 72 | 1 |
| Pricing and Reimbursement Process | 72 | 1 |
| Diagnosis Procedure Combination Reimbursement System in Japan - Immense Savings for the Government | 73 | 1 |
| Key Trends | 74 | 1 |
| Major Challenges | 74 | 1 |
| Australia | 74 | 1 |
| Pricing and Reimbursement Process | 75 | 1 |
| Key Trends | 76 | 1 |
| Major Challenges | 77 | 1 |
| Australia-United States Free Trade Agreement | 77 | 1 |
| China | 77 | 2 |
| Pricing and Reimbursement Process | 79 | 1 |
| Essential Medicine System to Offer Twin Benefits: Curb Rising Drug Prices and Easy Accessibility of Drugs | 79 | 1 |
| Drug Pricing Mechanism | 80 | 1 |
| NDRC Drug Pricing: Criteria for Evaluation | 81 | 1 |
| Differential Drug Pricing | 81 | 1 |
| Regulatory Authorities involved in Reimbursement of Drugs | 81 | 1 |
| Basic Healthcare Insurance System | 82 | 1 |
| Improved Basic Medical Insurance System | 82 | 1 |
| Key Trends | 82 | 1 |
| Price Cuts for the Second Time in 2011 | 82 | 1 |
| National Health Reforms | 82 | 1 |
| NDRL 2009 to Push Drug Sales in the Future | 83 | 1 |
| Major Challenges | 83 | 1 |
| Wide Gap between Need for Healthcare Services and Health Insurance | 83 | 1 |
| Cuts in Mark-up to Hard Hit Public Health Facilities | 84 | 1 |
| Price Cuts Ineffective in Curbing Healthcare Expenditure | 84 | 1 |
| Price Cuts and Hospital Tendering Process: Erosion of Generic Margins | 84 | 1 |
| Generic Brands Less Encouraged | 85 | 1 |
| India | 85 | 1 |
| Pricing and Reimbursement Process | 86 | 1 |
| Jan Aushadhi Shops | 87 | 1 |
| Health Insurance | 88 | 1 |
| Medical Reimbursement | 89 | 1 |
| Key Trends | 90 | 1 |
| Free Medicines Scheme | 90 | 1 |
| Generics Only Prescriptions by Government Doctors | 90 | 1 |
| Insurers Reducing Health Benefits | 90 | 1 |
| Major Challenges | 90 | 1 |
| Generic Drug Prices Set to Increase | 91 | 1 |
| Generic Drug Shortage | 91 | 1 |
| Pricing and Reimbursement in Generics - Appendix | 92 | 8 |
| Market Definitions | 92 | 1 |
| Abbreviations | 92 | 4 |
| Research Methodology | 96 | 3 |
| The US | 96 | 1 |
| Methodology | 96 | 1 |
| Sources of Coverage | 96 | 1 |
| Top Five Countries of Europe | 97 | 1 |
| Methodology | 97 | 1 |
| Sources of Coverage | 97 | 1 |
| Eastern Europe | 97 | 1 |
| Methodology | 97 | 1 |
| Sources of Coverage | 97 | 1 |
| Scandinavia | 97 | 1 |
| Methodology | 97 | 1 |
| Sources of Coverage | 97 | 1 |
| Asia-Pacific | 98 | 1 |
| Methodology | 98 | 1 |
| Sources of Coverage | 98 | 1 |
| Contact Us | 98 | 1 |
| Disclaimer | 98 | 1 |
| Sources | 98 | 2 |